10,877
Participants
Start Date
April 13, 2020
Primary Completion Date
November 3, 2021
Study Completion Date
May 31, 2022
Combination drug containing fimasartan and statins
"Patients who correspond to one of the following:~1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia~2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin~3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin"
Chonnam National University Hospital, Gwangju
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
INDUSTRY